Skip to content

Advertisement

  • Research article
  • Open Access

Hyporesponsiveness of natural killer cells and impaired inflammatory responses in critically ill patients

BMC ImmunologyBMC series – open, inclusive and trusted201718:48

https://doi.org/10.1186/s12865-017-0231-y

Received: 28 June 2017

Accepted: 5 December 2017

Published: 8 December 2017

Abstract

Background

To investigate natural killer (NK) cell activity, circulating cytokine level and peripheral blood mononuclear cell (PBMC) cytokine production status in critically ill patients.

Methods

Blood samples were collected <24 h after admission from 24 intensive care unit (ICU) patients and 24 age-, sex-, and body mass index (BMI)-matched healthy controls. Serum cytokine concentrations and cytokine production by PBMCs and lipopolysaccharide (LPS)-stimulated PBMCs were measured.

Results

The ICU group showed lower NK cell activity than the controls under all conditions and an absence of interferon (IFN)-γ. After adjusting for triglycerides, LDL- and HDL-cholesterol, and glucose, the ICU group exhibited lower serum levels of albumin and interleukin (IL)-12 and higher leukocyte counts and hs-CRP and IL-6 levels than the controls. Non-stimulated PBMCs from ICU patients secreted significantly greater amounts of IL-6 and IL-1β than the controls; however, the production of IL-6, TNF-α and IL-1β in response to LPS stimulation was significantly lower in the ICU group.

Conclusions

Significant reductions in NK cell activity and serum IL-12 level, an absence of serum IFN-γ, and decreased cytokine production from LPS-stimulated PBMCs indicate the hyporesponsiveness of NK cells and an impaired early phase inflammatory response in critically ill patients (ClinicalTrials.gov NCT02565589:). Retrospectively registered; October 1, 2015.

Keywords

CytokineICUInflammatory responseNK cellPBMC

Background

The host response to systemic infection and acute inflammatory states is characterized by fast and marked alterations in innate and adaptive immunity [1]. Critically ill patients with various conditions, including sepsis, trauma, burns, hemorrhagic shock, and severe surgery, show exacerbated production of proinflammatory mediators, a status that is called systemic inflammatory response syndrome (SIRS) [2]. In response to this proinflammatory state, there is a compensatory release of anti-inflammatory substances, a status that is called compensatory anti-inflammatory response syndrome (CARS) [2]. In general, proinflammatory reactions are thought to be responsible for collateral tissue damage in severe sepsis, whereas anti-inflammatory responses are implicated in enhanced susceptibility to secondary infections [3]. Accordingly, CARS often leads to suppression of the immune system, which makes patients vulnerable to nosocomial infections [4] and leads to increased morbidity and mortality in the ICU [2].

Critical illnesses can deregulate every component of the immune response [57]. In patients infected following surgery, trauma, or burn, circulating monocytes exhibit reduced production of IL-12 [8, 9]. Decreased monocyte interleukin (IL)-12 production was significantly correlated with adverse clinical outcomes [10]. Several circulating cytokines and cytokine production by peripheral blood mononuclear cells (PBMCs) play vital roles in critically ill patients [1113]. The stimulated level of whole blood cytokine production is theoretically a good indicator of host immunity because it reflects actual cell function, such as their ability to produce key cytokines involved in host defense [14]. In a prospective cohort clinical study, the number of CD14+ monocytes producing IL-12, tumor necrosis factor (TNF)-α, and IL-6 after lipopolysaccharide stimulation was 40% to 70% lower in trauma patients than in healthy control subjects [8]. Critically ill pediatric patients with persistently low stimulated TNF-α production are more likely to acquire life-threatening infections, and treatment caused rapid improvement in stimulated TNF-α production, which was associated with the prevention of nosocomial infections [15, 16].

NK cells are crucial components of the innate immune system, representing 10% of the cells in the total PBMC population of circulating human lymphocytes, which is the third largest lymphocyte population following B and T cells [17]. NK cells contribute to the immune-inflammatory reaction by producing many cytokines, particularly interferon (IFN)-γ, a potent immune-stimulating cytokine [18]. NK cells have a protective role during infection but can also be harmful during systemic inflammation and are associated with lethality and experimental sepsis [19, 20]. In a comparison of ICU patients with severe sepsis or septic shock or non-septic SIRS and healthy controls, septic patients exhibited reduced IFN-γ production by NK cells, whereas SIRS patients exhibited increased IFN-γ production compared to that of sepsis patients or healthy controls [21]. However, few studies have compared NK cell activity in non-septic, critically ill patients with that in healthy controls. Therefore, the aim of this study was to investigate NK cell activities, circulating cytokine levels, non-stimulated PBMC cytokine production, lipopolysaccharide (LPS)-stimulated PBMC cytokine production, and nutritional status in the early phase (< 24 h after ICU admission) in critically ill patients in comparison with age-, sex-, and body mass index (BMI)-matched healthy controls.

Methods

Study design

Critically ill patients (ICU group, n = 24) were enrolled between April 2015 and July 2015 from Yonsei University Severance Hospital after admission to the ICU. For validation of the experimental findings, age-, sex- and BMI-matched healthy subjects were enrolled as controls from a local health evaluation center during the same period (ClinicalTrials.gov: NCT02565589; http://www.clinicaltrials.gov). Among the critically ill patients, 16 patients had pulmonary disease, and 8 patients had trauma. Disease severity was evaluated with the Acute Physiology and Chronic Health Evaluation (APACHE) II score [22]. All of the patients were treated according to appropriate guidelines [23, 24]. Written informed consent was provided from the healthy participants and from a close family member for the ICU group. Institutional Review Board at Yonsei University Severance Hospital approved the study protocol, which was conducted according to the Declaration of Helsinki.

Anthropometric parameters, biochemical assessments, and cytokine and NK cell activity assays

Anthropometric parameters, serum lipid profiles, glucose, nutritional status, liver and renal function tests, cytokine levels in serum and PBMC supernatants, and NK cell activity were analyzed as previously described [25]. Detailed information about assessments of cytokine levels in serum and PBMC supernatants, and NK cell activity were described in supplementary information (See Additional File 1).

Statistical analysis

SPSS version 21.0 (IBM/SPSS Corp. Chicago, IL) was used for statistical analysis. Comparisons between the control and ICU groups were performed using the Chi-square test for categorical variables and independent t-tests for continuous variables. Adjustment for confounding variables was performed using an ANCOVA analysis. p-values under 0.05 were regarded as statistically significant, and p-values for skewed variables were analyzed using log-transformed data. The results are presented as the means ± standard errors, and untransformed values are presented for descriptive purposes. The relationships between variables were examined using Pearson’s correlation coefficient and visualized as a heat map.

Results

Clinical characteristics and serum cytokine levels

Compared with the age-, sex-, and BMI-matched healthy controls, the ICU group exhibited a significant decrease in triglycerides, total-, LDL- and HDL-cholesterol, albumin, prealbumin, IL-12, and IFN-γ levels and a significant increase in serum glucose, leukocyte count, and the serum levels of hs-CRP, IL-6 and IL-1β (Table 1). The ICU group exhibited an absence of IFN-γ (below the detection limit), in contrast to the control group. The ICU group displayed lower serum levels of albumin (p < 0.001), prealbumin (p = 0.010), and IL-12 (p = 0.012) and a higher leukocyte count (p = 0.012), hs-CRP (p < 0.001), and IL-6 (p < 0.001) levels than the control group after adjustment for triglycerides, LDL- and HDL-cholesterol and glucose levels.
Table 1

Clinical characteristics in control and ICU patient groups

 

Control group (n = 24)

ICU patient (n = 24)

p 0

p 1

Age (year)

64.5 ± 2.05

64.6 ± 3.06

0.991

 

Male/Female n, (%)

18 (75.0) / 6 (25.0)

18 (75.0) / 6 (25.0)

1.000

BMI (kg/m2)

22.3 ± 0.40

22.4 ± 0.77

0.977

Height (cm)

163.7 ± 1.82

166.7 ± 1.41

0.201

Weight (kg)

64.0 ± 2.06

62.5 ± 2.69

0.669

Glucose (mg/dL)

97.0 ± 4.95

211.4 ± 38.1

<0.001

Triglyceride (mg/dL)

135.5 ± 9.41

104.8 ± 8.85

0.018

Total-cholesterol (mg/dL)

216.3 ± 10.9

111.6 ± 7.16

<0.001

LDL-cholesterol (mg/dL)

129.2 ± 10.1

61.4 ± 5.81

<0.001

HDL-cholesterol (mg/dL)

59.8 ± 3.63

29.2 ± 2.85

<0.001

GOT (IU/L)

28.5 ± 2.34

35.8 ± 6.02

0.708

0.155

GPT (IU/L)

24.1 ± 1.91

22.2 ± 4.03

0.097

0.581

γ-GTP (U/L)

34.8 ± 8.53

51.4 ± 15.9

0.967

0.520

BUN (mg/dL)

15.1 ± 0.58

19.1 ± 2.54

0.811

0.294

Creatinine (mg/dL)

0.82 ± 0.03

0.83 ± 0.07

0.556

0.567

Albumin (mg/dL)

4.94 ± 0.11

2.77 ± 0.11

<0.001

<0.001

Prealbumin (mg/dL)

25.6 ± 0.97

10.7 ± 0.97

<0.001

0.010

Leukocyte count (×103/μL)

5.65 ± 0.25

10.8 ± 0.92

<0.001

0.012

hs-CRP (mg/L)

1.01 ± 0.29

113.1 ± 15.1

<0.001

<0.001

IL-12 (pg/mL)

41.5 ± 7.78

2.49 ± 1.59

<0.001

0.012

IFN-γ (pg/mL)

14.8 ± 2.61

0.00 ± 0.00

<0.001

0.031

TNF-α (pg/mL)

11.7 ± 2.27

6.49 ± 0.70

0.094

0.816

IL-6 (pg/mL)

2.55 ± 0.28

56.4 ± 16.9

<0.001

<0.001

IL-1β (pg/mL

0.56 ± 0.05

2.54 ± 0.15

0.001

0.091

Mean ± SE.tested by logarithmic transformation. p 0: derived from independent t-test. p 1: adjusted for glucose, triglyceride, LDL-cholesterol, and HDL-cholesterol

NK cell activity and PBMC cytokine production in response to LPS in ICU patients

NK cell activities determined in all conditions (E:T = 10:1, 5:1, 2.5:1 and 1.25:1) were significantly lower in the ICU group than the control group (Table 2). Cytokine levels measured in cultured PBMC supernatants following LPS stimulation (0, 5, 10 ng/mL) for the control and ICU groups are shown in Table 2. Non-stimulated PBMCs from ICU patients secreted significantly greater amounts of IL-6 and IL-1β into the culture media than those from healthy controls. Both the control and patient groups showed increases in the levels of TNF-α, IL-6 and IL-1β after LPS stimulation. However, the production of IL-6 and TNF-α in response to LPS stimulation (5 or 10 ng/mL) was lower in the ICU group than the control group. Similarly, the production of IL-1β in response to LPS stimulation (10 ng/mL) was lower in the ICU group compared to the control group (p = 0.001).
Table 2

Natural killer cell activities and cytokine production from PBMCs

 

Control group (n = 24)

ICU patient (n = 24)

p

NK cell activity

 NK cell activity E:T = 10:1 (%)

27.4 ± 2.37

16.4 ± 1.99

0.002

 NK cell activity E:T = 5:1 (%)

20.8 ± 1.85

13.1 ± 2.15

0.006

 NK cell activity E:T = 2.5:1 (%)

20.1 ± 2.20

13.0 ± 1.94

0.011

 NK cell activity E:T = 1.25:1 (%)

23.1 ± 2.24

15.1 ± 2.19

0.013

Non-stimulated PBMC

 TNF-α (pg/mL)

2.03 ± 0.31

5.26 ± 1.48

0.103

 IL-6 (pg/mL)

12.1 ± 3.57

19.9 ± 3.29

0.039

 IL-1β (pg/mL)

0.70 ± 0.24

2.58 ± 0.51

0.002

PBMC (LPS 5 ng/mL)

 TNF-α (pg/mL)

299.7 ± 42.5

173.0 ± 39.2

0.007

 IL-6 (pg/mL)

2045.3 ± 341.9

685.9 ± 238.8

0.025

 IL-1β (pg/mL)

22.5 ± 5.90

18.0 ± 6.79

0.304

PBMC (LPS 10 ng/mL)

 TNF-α (pg/mL)

322.3 ± 49.2

210.5 ± 57.7

0.015

 IL-6 (pg/mL)

2479.2 ± 369.2

498.9 ± 108.4

<0.001

 IL-1β (pg/mL)

24.7 ± 3.77

15.2 ± 4.92

0.001

Mean ± SE.tested by logarithmic transformation. p: derived from independent t-test

Correlations among age, BMI, leukocyte count, serum levels of hs-CRP, albumin, and prealbumin, and PBMC cytokine production

In the ICU group, there were significant positive correlations among BMI, serum albumin, and serum prealbumin. Serum prealbumin was weakly and negatively correlated with age (r = −0.480, p = 0.021), moderately correlated with hs-CRP (r = −0.530, p = 0.009), and positively correlated with PBMC TNF-α production after LPS stimulation (5 ng/mL) (r = 0.625, p = 0.002), which was also associated with BMI (r = 0.567, p = 0.007) and serum albumin (r = 0.633, p = 0.002). Non-stimulated PBMC IL-6 was positively associated with non-stimulated PBMC IL-1β (r = 0.695, p < 0.001), which had a strong positive correlation with LPS (5 ng/mL)-stimulated PBMC IL-1β (r = 0.789, p < 0.001) and a low positive correlation with TNF-α (r = 0.468, p = 0.033). There were positive correlations among LPS (5 ng/mL)-stimulated PBMC IL-1β, LPS-stimulated PBMC TNF-α, and LPS-stimulated IL-6 (Fig. 1).
Figure 1
Fig. 1

Correlation matrix among clinical and inflammatory parameters in control and ICU patient groups. Correlations were obtained by deriving Pearson’s correlation coefficient. Red denotes a positive correlation, and blue denotes a negative correlation

In the control group, serum prealbumin was negatively correlated with age (r = −0.611, p = 0.002). BMI was positively and weakly correlated with the leukocyte count (r = 0.482, p = 0.017) and negatively correlated with non-stimulated PBMC TNF-α (r = −0.463, p = 0.026), which was negatively associated with leukocyte count (r = −0.571, p = 0.004) and positively associated with serum albumin (r = 0.510, p = 0.013). Non-stimulated PBMC TNF-α exhibited positive but weak correlation with non-stimulated PBMC IL-1β (r = 0.458, p = 0.028). Non-stimulated PBMC IL-6 was strongly and positively correlated with non-stimulated PBMC IL-1β (r = 0.779, p < 0.001), which showed positive but weak correlation with LPS (5 ng/mL)-stimulated PBMC IL-1β (r = 0.484, p = 0.017) and IL-6 (r = 0.455, p = 0.025). There were strong positive correlations among LPS (5 ng/mL)-stimulated PBMC IL-1β, TNF-α, and IL-6 (Fig. 1).

Discussion

This study showed that NK cell activities were significantly decreased under all conditions (E:T = 10:1, 5:1, 2.5:1, and 1.25:1) in the early phase in critically ill patients compared with those in age-, sex-, and BMI-matched healthy controls. This finding is in accordance with another recent study suggesting that NK cells and monocytes exhibit hyporesponsiveness during critical illness [26]. NK cells have the capacity to induce apoptosis or cell lysis in tumor cells, virus-infected cells, and intracellular parasites [27]. NK cells play an immuno-modulatory role by secreting several cytokines, including IFN-γ, which activates many key pathways related to antiviral functions [17]. IL-12 is involved in stimulation of IFN-γ production from T cells and NK cells [28]. Thus, the large reduction in NK cell activity and serum IL-12 levels as well as the absence of serum IFN-γ observed in the ICU group in this study indicate NK cell hyporesponsiveness during the early phase in critically ill patients.

Increased IL-12 production may be associated with increased cellular immunity in critically ill patients. For instance, LPS-stimulated PBMCs from survivors with severe sepsis produced more IL-12 and less IL-10 than those from nonsurvivors [12]. Similarly, the LPS-stimulated PBMCs from survivors with septic shock produced more TNF-α than those from nonsurvivors [29]. In this study, serum TNF-α and TNF-α production by non-stimulated PBMCs were not significantly different between the control and ICU groups, while TNF-α production in response to LPS stimulation (5, 10 ng/mL) was significantly lower in the ICU group than the healthy controls. Additionally, TNF-α production in response to LPS stimulation (5 ng/mL) in the ICU group was positively correlated with nutritional status, including BMI and the serum concentrations of albumin and prealbumin. However, this association was not observed in the healthy controls. Patients showing impaired TNF-α production in leukocytes upon ex vivo LPS stimulation have been reported to exhibit an increased risk of developing nosocomial infections [30]. Therefore, the positive correlation between TNF-α production in response to LPS stimulation and nutritional status and the negative correlation between hs-CRP and prealbumin observed in the ICU group in this study suggest the importance of nutritional therapy in critically ill patients to improve health outcomes, including cellular immunity [3134].

Serum hs-CRP levels have been reported to positively correlate with serum IL-6, which is always increased in acutely ill patients with severe sepsis [26, 35]. Similarly, the ICU group in this study showed higher serum levels of hs-CRP and IL-6 and leukocyte count than the control group. Furthermore, the production of IL-6 and IL-1β by non-stimulated PBMCs was higher in the ICU group, although the production of IL-6 and IL-1β in response to LPS stimulation was lower in the ICU group. There is an age-related decline in cytokine production by monocytes, particularly for the proinflammatory mediators IL-6, TNF-α, and IL-1β [3640]. Indeed, older patients are known to exhibit less effective neutrophil activity [37] and decreased NK cell cytotoxicity and macrophage function [39, 41]. However, the lower cytokine production following LPS stimulation in the ICU group could have resulted from critical illness, including pneumonia and trauma, rather than age, sex, or low body weight, as the healthy controls were age-, sex-, and BMI-matched to the critically ill patients in this study. In this study, there was a closer correlation between IL-6, TNF-α, and IL-1β levels from LPS-stimulated PBMCs from the healthy controls compared with the ICU group.

The limitations of this study must be addressed. First, the sample size of 24 critically ill patients warrants confirmation in larger trials. Second, the study was an observational study, in which elucidating the cause and effect relationships of specific (immunological and inflammatory) mechanisms was not possible. Finally, our results do not directly demonstrate that NK cell hyporesponsiveness in the ICU group was significantly correlated with decreased IL-12 and IFN-γ. Despite these limitations, we observed greater reductions in NK cell activities and serum IL-12 levels and an absence of serum IFN-γ in the early phase in critically ill patients than in age-, sex-, and BMI-matched healthy controls. We also detected a decrease in serum albumin and prealbumin and an increase in the leukocyte count, serum IL-6, and hs-CRP. Furthermore, in contrast to the increased production of IL-6 and IL-1β from non-stimulated PBMCs, the decreased production of IL-6, TNF-α, and IL-1β from LPS-stimulated PBMCs in the ICU group suggest an impaired inflammatory response in critically ill patients.

Conclusions

This study investigated NK cell activities, circulating cytokine levels and PBMC cytokine production status in critically ill patients. The ICU group showed lower NK cell activities and serum levels of albumin and IL-12 and higher leukocyte counts and hs-CRP and IL-6 levels than the controls. Non-stimulated PBMCs from ICU patients secreted significantly higher amounts of IL-6 and IL-1β than those from controls, while production of IL-6 and TNF-α in response to LPS stimulation (5 or 10 ng/mL) was lower in the ICU group. Similarly, the production of IL-1β in response to LPS stimulation (10 ng/mL) was also significantly lower in the ICU group. Our findings suggest that great reductions in NK cell activities and serum IL-12 levels, an absence of serum IFN-γ, and decreased cytokine production from LPS-stimulated PBMCs could indicate the hyporesponsiveness of NK cells and an impaired inflammatory response in the early phase of critical illness.

Abbreviations

BMI: 

Body mass index

BUN: 

Blood urea nitrogen

CARS: 

Compensatory anti-inflammatory response syndrome

GOT: 

Glutamic oxaloacetic transaminase

GPT: 

Glutamic pyruvate transaminase

hs-CRP: 

High-sensitivity C-reactive protein

ICU: 

Intensive care unit

IFN: 

Interferon

IL: 

Interleukin

LPS: 

Lipopolysaccharide

NK: 

Natural killer

PBMC: 

Peripheral blood mononuclear cell

SIRS: 

Systemic inflammatory response syndrome

TNF: 

Tumor necrosis factor

γ-GTP: 

Gamma-glutamyl transpeptidase

Declarations

Acknowledgements

Not applicable.

Funding

This work was supported by the Bio-Synergy Research Project (NRF-2012M3A9C4048762) of the Ministry of Science, ICT and Future Planning through the National Research Foundation, Republic of Korea.

Availability of data and materials

The data that support the findings of this study are available on request from the corresponding author [JHL].

Authors’ contributions

Sample collection and experiments were performed by MJK, HJ, JSC, YSK, JGL, YC, and JHL. Data were analyzed and interpreted by MKK and JHL. JHL provided the research funding, and MKK and JHL wrote the manuscript. All authors critically revised the manuscript, read and approved the final manuscript, and agree to be fully accountable for ensuring the integrity and accuracy of the work.

Ethics approval and consent to participate

Written informed consent was provided by a close family member. This investigation was approved by the Institutional Review Board at Yonsei University Severance Hospital (Seoul, Korea; Approval Number: 4–2013-0902) and conducted according to the Helsinki Declaration.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Research Center for Silver Science, Institute of Symbiotic Life-TECH, Yonsei University, Seoul, Republic of Korea
(2)
National Leading Research Laboratory of Clinical Nutrigenetics/Nutrigenomics, Department of Food and Nutrition, College of Human Ecology, Yonsei University, Seoul, Republic of Korea
(3)
Department of Food and Nutrition, Brain Korea 21 PLUS Project, College of Human Ecology, Yonsei University, Seoul, Republic of Korea
(4)
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
(5)
Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea
(6)
Department of Nutrition, Yonsei University Health System, Seoul, Republic of Korea

References

  1. Andaluz-Ojeda D, Iglesias V, Bobillo F, et al. Early levels in blood of immunoglobulin M and natural killer cells predict outcome in nonseptic critically ill patients. J Crit Care. 2013;28:1110.View ArticlePubMedGoogle Scholar
  2. Adib-Conquy M, Cavaillon JM. Compensatory anti-inflammatory response syndrome. Thromb Haemost. 2009;101:36–47.PubMedGoogle Scholar
  3. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369:840–51.View ArticlePubMedGoogle Scholar
  4. Ward NS, Casserly B, Ayala A. The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin Chest Med. 2008;29:617–25.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Monneret G, Venet F, Kullberg BJ, Netea MG. ICU-acquired immunosuppression and the risk for secondary fungal infections. Med Mycol. 2011;49(Suppl 1):S17–23.View ArticlePubMedGoogle Scholar
  6. Opal SM. Immunologic alterations and the pathogenesis of organ failure in the ICU. Semin Respir Crit Care Med. 2011;32:569–80.View ArticlePubMedGoogle Scholar
  7. Marshall JC, Charbonney E, Gonzalez PD. The immune system in critical illness. Clin Chest Med. 2008;29:605–16. viiView ArticlePubMedGoogle Scholar
  8. Spolarics Z, Siddiqi M, Siegel JH, et al. Depressed interleukin-12-producing activity by monocytes correlates with adverse clinical course and a shift toward Th2-type lymphocyte pattern in severely injured male trauma patients. Crit Care Med. 2003;31:1722–9.View ArticlePubMedGoogle Scholar
  9. Weighardt H, Heidecke CD, Westerholt A, et al. Impaired monocyte IL-12 production before surgery as a predictive factor for the lethal outcome of postoperative sepsis. Ann Surg. 2002;235:560–7.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Miyazaki M. Immunosuppression following surgical and traumatic injury. Surg Today. 2010;40:793–808.View ArticlePubMedGoogle Scholar
  11. Wu HP, Shih CC, Chu CM, et al. Effect of interleukin-17 on in vitro cytokine production in healthy controls and patients with severe sepsis. J Formos Med Assoc. 2015;114:1250–7.View ArticlePubMedGoogle Scholar
  12. Wu HP, Shih CC, Lin CY, Hua CC, Chuang DY. Serial increase of IL-12 response and human leukocyte antigen-DR expression in severe sepsis survivors. Crit Care. 2011;15:R224.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Hamers L, Kox M, Pickkers P. Sepsis-induced immunoparalysis: mechanisms, markers, and treatment options. Minerva Anestesiol. 2015;81:426–39.PubMedGoogle Scholar
  14. Drewry AM, Ablordeppey EA, Murray ET, et al. Comparison of monocyte human leukocyte antigen-DR expression and stimulated tumor necrosis factor alpha production as outcome predictors in severe sepsis: a prospective observational study. Crit Care. 2016;20:334.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Hall MW, Knatz NL, Vetterly C, et al. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med. 2011;37:525–32.View ArticlePubMedGoogle Scholar
  16. Hall MW, Geyer SM, Guo CY, et al. Innate immune function and mortality in critically ill children with influenza: a multicenter study. Crit Care Med. 2013;41:224–36.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Mandal A, Viswanathan C. Natural killer cells: in health and disease. Hematol Oncol Stem Cell Ther. 2015;8:47–55.View ArticlePubMedGoogle Scholar
  18. Huntington ND, Vosshenrich CA, Di Santo JP. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol. 2007;7:703–14.View ArticlePubMedGoogle Scholar
  19. Badgwell B, Parihar R, Magro C, Dierksheide J, Russo T, Carson WE 3rd. Natural killer cells contribute to the lethality of a murine model of Escherichia Coli infection. Surgery. 2002;132:205–12.View ArticlePubMedGoogle Scholar
  20. Etogo AO, Nunez J, Lin CY, Toliver-Kinsky TE, Sherwood ER. NK but not CD1-restricted NKT cells facilitate systemic inflammation during polymicrobial intra-abdominal sepsis. J Immunol. 2008;180:6334–45.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Forel JM, Chiche L, Thomas G, et al. Phenotype and functions of natural killer cells in critically-ill septic patients. PLoS One. 2012;7:e50446.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–29.View ArticlePubMedGoogle Scholar
  23. Dellinger RP, Carlet JM, Masur H, et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32:858–73.View ArticlePubMedGoogle Scholar
  24. Dellinger RP, Levy MM, Carlet JM, et al. Surviving se psis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36:296–327.View ArticlePubMedGoogle Scholar
  25. Lee JG, Kim YS, Lee YJ, et al. Effect of immune-enhancing Enteral nutrition enriched with or without Beta-Glucan on Immunomodulation in critically ill patients. Nutrients. 2016;8:336.View ArticlePubMed CentralGoogle Scholar
  26. Kjaergaard AG, Nielsen JS, Tønnesen E, Krog J. Expression of NK cell and monocyte receptors in critically ill patients--potential biomarkers of sepsis. Scand J Immunol. 2015;81:249–58.View ArticlePubMedGoogle Scholar
  27. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331:44–9.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3:133–46.View ArticlePubMedGoogle Scholar
  29. Stanilova SA, Karakolev ZT, Dimov GS, et al. High interleukin 12 and low interleukin 10 production after in vitro stimulation detected in sepsis survivors. Intensive Care Med. 2005;31:401–7.View ArticlePubMedGoogle Scholar
  30. Landelle C, Lepape A, Voirin N, et al. Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock. Intensive Care Med. 2010;36:1859–66.View ArticlePubMedGoogle Scholar
  31. Calder PC, Jensen GL, Koletzko BV, Singer P, Wanten GJ. Lipid emulsions in parenteral nutrition of intensive care patients: current thinking and future directions. Intensive Care Med. 2010;36:735–49.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Ott J, Hiesgen C, Mayer K. Lipids in critical care medicine. Prostaglandins Leukot Essent Fatty Acids. 2011;85:267–73.View ArticlePubMedGoogle Scholar
  33. Barros KV, Cassulino AP, Schalch L, et al. Pharmaconutrition: acute fatty acid modulation of circulating cytokines in elderly patients in the ICU. JPEN J Parenter Enteral Nutr. 2014;38:467–74.View ArticlePubMedGoogle Scholar
  34. Giger U, Büchler M, Farhadi J, et al. Preoperative immunonutrition suppresses perioperative inflammatory response in patients with major abdominal surgery-a randomized controlled pilot study. Ann Surg Oncol. 2007;14:2798–806.View ArticlePubMedGoogle Scholar
  35. Damas P, Ledoux D, Nys M, et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg. 1992;215:356–62.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Shaw AC, Joshi S, Greenwood H, Panda A, Lord JM. Aging of the innate immune system. Curr Opin Immunol. 2010;22:507–13.View ArticlePubMedPubMed CentralGoogle Scholar
  37. Valente SA, Fallon WF Jr, Alexander TS, et al. Immunologic function in the elderly after injury--the neutrophil and innate immunity. J Trauma. 2009;67:968–74.View ArticlePubMedGoogle Scholar
  38. Brüünsgaard H, Pedersen BK. Age-related inflammatory cytokines and disease. Immunol Allergy Clin N Am. 2003;23:15–39.View ArticleGoogle Scholar
  39. Gomez CR, Karavitis J, Palmer JL, et al. Interleukin-6 contributes to age-related alteration of cytokine production by macrophages. Mediat Inflamm. 2010;2010:475139.View ArticleGoogle Scholar
  40. Ottinger ME, Monaghan SF, Gravenstein S, Cioffi WG, Ayala A, Heffernan DS. The geriatric cytokine response to trauma: time to consider a new threshold. Surg Infect. 2014;15:800–5.View ArticleGoogle Scholar
  41. Jing Y, Shaheen E, Drake RR, Chen N, Gravenstein S, Deng Y. Aging is associated with a numerical and functional decline in plasmacytoid dendritic cells, whereas myeloid dendritic cells are relatively unaltered in human peripheral blood. Hum Immunol. 2009;70:777–84.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement